Thu, Jan 29, 2015, 2:19 PM EST - U.S. Markets close in 1 hr 41 mins


% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • tredleon tredleon Oct 22, 2008 5:33 PM Flag

    While Today's "Encouraging" News...

    may seem underwhelming, remember that this is TH-302 as a monotherapy, and the pre-clinical evidence is that the real power is when used in combination - there is a synergistic impact shown in the pre-clinical studies where 1+1=4 in terms of tumor reduction and survival.
    And if you think that is irrational hyperbole, remember that TH-302 is targeted to attack the portions of the tumor that traditional chemo does not reach, and may be responsible for relapse and/or metastisis. No doubt, the single agent impact in these studies seems underwhelming, but remember, these are late-stage patients with runaway cancer that have already failed traditional treatments - nothing but a miracle could stop these people's cancers from progressing. So, the fact that they have generated a decent safety profile with some signs of response (it can't kill the entire tumor, only the hypoxic regions) is a good sign. The combination trials will be the true test of this drug, so hold on to your shares.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • These results are laughable. TH-302 certainly does NOT appear to work as well as it did for mice. Someone got HERPES from this drug??? Gee. Another B Slick bowel movement. I cannot believe Stutter, Tang, etc. just lost another $17 million on this. Wow! Too funny.

      I've written this off as a total loss, so I don't care what happens at this point. ANY good news sending the stock up would feel like winning the lottery - free money.

      But still, I cannot believe the poor timing for those suckers. Where is Michael Powell? He and his sister Denise must feel soooo proud. Quite a family effort to decimate so many shareholders. Ha!

      The stock market reflects my pessism: THLD down 25% today. Bankruptcy for sure.

      This would have to go to $90 to equal it's $15 pre split high. From 45 cents to $90? Could happen!

      • 1 Reply to SMAC693
      • SMAC - you're the one who was pumping the pre-clinical/mice studies before and I kept warning you that the monotherapy studies for TH-302 were worthless. Go back to the slide show - TH-302 as a single agent always performed worse (in terms of "response" and survival) than the current standard of care chemo agent. But this makes complete sense - traditional chemo reaches the larger portion of the tumor feeding off of the vasculature, while TH-302 reaches the smaller hypoxic regions of the tumor. Neither treatment on its own can kill the entire tumor - it is only when they combined them that they showed the dramatic "cure" rates in the mice. Given the dultion that has been crammed down on shareholders, this will never be a home run, but you could get a decent chunk of your money back?

3.72+0.07(+1.92%)2:19 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.